![]() Second Chance Sampling Research Topline Report, (May 2015). ![]() It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of your Healthcare Provider.ġ. The information brought to you by Ascensia Diabetes Care US Inc. Ascensia Diabetes Care reserves the right to cancel or change this offer at any time and without notice. This offer cannot be combined with any other offer. YOU ALSO CERTIFY THAT YOU WILL COMPLY WITH ANY TERMS OF YOUR HEALTH INSURANCE CONTRACT REQUIRING THAT YOUR PAYOR BE NOTIFIED OF THE EXISTENCE AND/OR VALUE OF THIS OFFER. Patient: BY USING THIS CARD, YOU UNDERSTAND AND AGREE TO COMPLY WITH THE RESTRICTIONS. Visit for additional details and Restrictions. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If patient is eligible for drug benefits under any such program, offer not valid. RESTRICTIONS: Offer not valid for prescriptions reimbursed under Medicaid, Medicare drug benefit plan, Tricare or other federal or state health programs (i.e. Patients pay all applicable taxes and fees. PATIENTS are responsible for any remaining balance after discount is applied. Excludes 15, 35 and 70 count over the counter test strips. CASH PATIENTS pay the first $15 and can save up to $66 on 100 count test strips. ELIGIBLE PRIVATELY INSURED PATIENTS pay the first $15 and can save up to $105 of remaining copay based upon prescription quantity and insurance coverage. We are excited that Insulet recognizes the value the CONTOUR ®NEXT ONE BGMS can bring to users of Omnipod's product platform.*Valid for up to 12 uses through. “One aspect of this is pump therapy, where we have established ourselves as the partner of choice for blood glucose monitoring in the pump sector. We believe that integrated diabetes management is the future and are happy to work with partners that will help us to achieve this goal together. Michael added, "This alliance is the next step in our goal of providing integrated solutions for people living with diabetes. In a clinical study, 95% of blood glucose results obtained with the CONTOUR ®NEXT ONE BGMS were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests. ![]() The CONTOUR ®NEXT ONE BGMS received 510(k) clearance from the FDA in November 2016 and has been shown to meet the stricter accuracy requirements of the FDA Over-the-Counter BGMS Guidance that was recently issued in 2016. "We are thrilled to partner with Ascensia as part of our development efforts on our next-generation Omnipod Dash™ platform, which will allow Insulet to maintain its competitive edge with truly innovative and differentiated products," said Shacey Petrovic, President and Chief Operating Officer. We are pleased that our highly accurate system has been chosen to provide the critical blood glucose data that will be used by the Omnipod Dash™ PDM to calculate insulin dosing for patients." "The integration of our BGM system with Insulet's tubeless insulin pump system has significant potential to help people take control of their lives and their diabetes. "We are delighted to enter into this agreement that brings together these innovative technologies from both companies," said Michael Kloss, CEO, Ascensia Diabetes Care. ![]() Under the terms of this worldwide non-exclusive agreement, Insulet will develop and seek marketing clearance for the Omnipod Dash™ PDM, with collaboration from Ascensia Diabetes Care who will provide the CONTOUR ®NEXT ONE meter and CONTOUR ®NEXT test strips. These readings will be used by the Omnipod Dash™ PDM to calculate insulin dosing and support highly accurate delivery of insulin for people living with diabetes. ![]() The CONTOUR ®NEXT ONE BGMS will pair, via Bluetooth Low Energy (BLE), with the Omnipod Dash™ Personal Diabetes Manager (Omnipod Dash™ PDM) to automatically transmit a person's blood glucose readings directly into the system. Seamlessly connecting the CONTOUR ®NEXT ONE BGMS and the Omnipod Dash™ System will provide people living with diabetes with an innovative continuous insulin delivery system to manage their diabetes, powered by remarkably accurate blood glucose readings. Under the terms of this agreement, the Ascensia CONTOUR ®NEXT ONE blood glucose monitoring system (BGMS) will connect to Insulet's next-generation Omnipod System (the Omnipod Dash™ System), which is currently in development. Ascensia Diabetes Care announced it has entered into a strategic alliance by signing a development agreement with Insulet, the leader in tubeless insulin pump technology with its Omnipod Insulin Management System (the Omnipod System). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |